HC@AIxIA: AI&Health Seminar - OCTOBER 21 AI in PCNSL: a diagnostic and therapeutic journey
Dear Madam/Sir,
This is to officially announce the NINTH seminar of the "AI & Health" series as hosted by HC@AIxIA, i.e., the "Artificial Intelligence for Healthcare" working group of the Italian Association for Artificial Intelligence.
*** Save the date: 21 OCTOBER 2024. ***
We hope you will attend and participate in the discussion on the relevant topics that will be presented and by our speakers. Feel free to share this with those potentially interested.
Please find some details below, and a poster attached. All directions for participating are available at https://aixia.it/en/gruppi/hc/.
== Are you interested in Joining the group? ==
Please head to https://aixia.it/en/gruppi/hc/ fo find out how. Do not hesitate to contact us at hc-aixia@googlegroups.com for any information or clarification.
Thank you for your interest in the AI & Health seminar series and the HC@AIxIA working group, and see you soon!
Sincerely,
Francesco Calimeri, Mauro Dragoni, Fabio Stella
(coordinators of the HC@AIxIA working group)
Link to participate: https://unimib.webex.com/unimib/j.php?MTID=m447969fc152aadf2062314114be484a6
2024 October 21 - 4:30PM CET
Teresa Calimeri, Senior Staff Physician Lymphoma Unit, IRCCS San Raffale Hospital (Milan, Italy)
- joint with Nicoletta Anzalone, Head of the Neuroradiology Unit of Advanced Vascular Imaging, IRCCS San Raffale Hospital, Milan, Italy, and Michela Destito, Department of Experimental and Clinical Medicine, University “Magna Graecia” of Catanzaro, Catanzaro, Italy).
Short Bio: Teresa Calimeri, MD PhD, works in the Lymphoma Unit of the IRCCS San Raffaele Hospital, Milan, Italy as a senior staff physician and she has been recently identified as the clinical coordinator of the Disease Unit Lymphoma. Dr. Calimeri’s personal research focus includes the molecular characterization of primary and secondary CNS lymphomas along with the applications of circulating tumor DNA (ctDNA) as a biomarker of diagnosis, treatment response and disease prognosis. Dr. Calimeri has also recently promoted and launched a collaboration with biomedical and informatic engineers with the aim to apply radiomic and deep learning approaches for the studies of lymphoid malignancies. Moreover, she is deeply involved in the clinical management of indolent and aggressive lymphomas. She spent part of her PhD in Molecular Oncology at The Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute & Harvard Medical School in Boston. In 2017, she also completed a II Level Master course in the diagnosis and therapy of Lymphomas at the University of Udine sponsored by the Fondazione Italiana Linfomi. She is member of both European and International PCNSL Collaborative Group (EPCG and IPCG). She is actively involved in the projects of the Fondazione Italiana Linfomi (FIL) and International Extranodal Lymphoma Study Group (IELSG).
This is to officially announce the NINTH seminar of the "AI & Health" series as hosted by HC@AIxIA, i.e., the "Artificial Intelligence for Healthcare" working group of the Italian Association for Artificial Intelligence.
*** Save the date: 21 OCTOBER 2024. ***
We hope you will attend and participate in the discussion on the relevant topics that will be presented and by our speakers. Feel free to share this with those potentially interested.
Please find some details below, and a poster attached. All directions for participating are available at https://aixia.it/en/gruppi/hc/.
== Are you interested in Joining the group? ==
Please head to https://aixia.it/en/gruppi/hc/ fo find out how. Do not hesitate to contact us at hc-aixia@googlegroups.com for any information or clarification.
Thank you for your interest in the AI & Health seminar series and the HC@AIxIA working group, and see you soon!
Sincerely,
Francesco Calimeri, Mauro Dragoni, Fabio Stella
(coordinators of the HC@AIxIA working group)
Link to participate: https://unimib.webex.com/unimib/j.php?MTID=m447969fc152aadf2062314114be484a6
2024 October 21 - 4:30PM CET
Teresa Calimeri, Senior Staff Physician Lymphoma Unit, IRCCS San Raffale Hospital (Milan, Italy)
- joint with Nicoletta Anzalone, Head of the Neuroradiology Unit of Advanced Vascular Imaging, IRCCS San Raffale Hospital, Milan, Italy, and Michela Destito, Department of Experimental and Clinical Medicine, University “Magna Graecia” of Catanzaro, Catanzaro, Italy).
Title: AI in PCNSL: a diagnostic and therapeutic journey
Abstract: The integration of Artificial Intelligence (AI) in the field of oncology represents one of the most significant challenges of the near future. Recent studies indicate that radiomic features can assist radiologists in addressing diagnostic and prognostic healthcare challenges, potentially ushering in a new era of personalized medicine. In this seminar, we will discuss our experience with primary central nervous system lymphoma (PCNSL) as a case study. Initially, we will delineate the constraints of the current diagnostic and prognostic tools. Subsequently, we will illustrate the application of a radiomics-based machine learning model and a deep learning (DL) approach to enhance the precision of outcome prediction. Furthermore, we will present our ideas on the possible application of these models in the treatment path of patients, along with the potential integration of a composite genetic and radiomic (radiogenomics) risk-adapted strategy. This strategy could be studied, validated, and routinely used during PCNSL treatment. Through case studies and recent research findings, this seminar aims to provide a comprehensive overview of the current state and future potential of AI in PCNSL management. (joint work with Nicoletta Anzalone, Head of the Neuroradiology Unit of Advanced Vascular Imaging, IRCCS San Raffale Hospital, Milan, Italy, and Michela Destito, Department of Experimental and Clinical Medicine, University “Magna Graecia” of Catanzaro, Catanzaro, Italy).Short Bio: Teresa Calimeri, MD PhD, works in the Lymphoma Unit of the IRCCS San Raffaele Hospital, Milan, Italy as a senior staff physician and she has been recently identified as the clinical coordinator of the Disease Unit Lymphoma. Dr. Calimeri’s personal research focus includes the molecular characterization of primary and secondary CNS lymphomas along with the applications of circulating tumor DNA (ctDNA) as a biomarker of diagnosis, treatment response and disease prognosis. Dr. Calimeri has also recently promoted and launched a collaboration with biomedical and informatic engineers with the aim to apply radiomic and deep learning approaches for the studies of lymphoid malignancies. Moreover, she is deeply involved in the clinical management of indolent and aggressive lymphomas. She spent part of her PhD in Molecular Oncology at The Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute & Harvard Medical School in Boston. In 2017, she also completed a II Level Master course in the diagnosis and therapy of Lymphomas at the University of Udine sponsored by the Fondazione Italiana Linfomi. She is member of both European and International PCNSL Collaborative Group (EPCG and IPCG). She is actively involved in the projects of the Fondazione Italiana Linfomi (FIL) and International Extranodal Lymphoma Study Group (IELSG).
orcid.org/0000-0002-0192-8965